{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:40:40Z","timestamp":1791423640090,"version":"4.3.3"},"reference-count":31,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T00:00:00Z","timestamp":1261094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Objective\u2002<\/jats:bold>\n                    To investigate the long\u2010term outcome of fractionated stereotactic radiotherapy (FSRT) [45\u2003Gy (range 45\u201354) in 25 fractions] in patients with pituitary adenomas characterized by tumour progression or hormonally active disease despite surgery and\/or medical therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Design\u2002<\/jats:bold>\n                    This was an observational follow\u2010up study of 5\u00b725\u2003years (median; range 1\u00b77\u201310\u00b74).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and measurements\u2002<\/jats:bold>\n                    Pituitary tumour volume, visual acuity\/fields, hypersecretion, hypopituitarism, cerebrovascular disease, second brain tumours and mortality were examined at regular intervals after FSRT in 30 patients with pituitary adenomas (20 nonfunctioning macroadenomas, 10 functioning). Prior to FSRT, 83% had been operated 1\u20133 times, 47% had visual field deficits\/impaired vision and 50% pituitary dysfunction. Progressive disease, stable disease, partial and complete tumour response were defined by MRI.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results\u2002<\/jats:bold>\n                    Tumour growth control was 100%. At the end of follow\u2010up, 30% had stable disease, 60% partial and 10% complete tumour response. Visual function was preserved and 36% of patients with prior field deficits improved. GH decreased from 4\u00b72 (range, 2\u00b73\u20136\u00b75) to 1\u00b71 (range, 0\u00b75\u20131\u00b75)\u2003\u03bcg\/l (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030\u00b7001) in patients with acromegaly, and medical therapy could be reduced. In large prolactinomas, partial response or complete tumour response was achieved. FSRT was well tolerated. Pituitary function remained normal in 27%, 33% of patients had stable dysfunction, 17% deteriorated further and 23% developed new dysfunction. There were no cerebrovascular events, second brain tumours or FSRT\u2010related deaths.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion\u2002<\/jats:bold>\n                    According to this long\u2010term follow\u2010up study, FSRT is an efficient and safe adjuvant therapy for pituitary adenomas refractory to conventional treatments.\n                  <\/jats:p>","DOI":"10.1111\/j.1365-2265.2009.03755.x","type":"journal-article","created":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T09:45:12Z","timestamp":1261129512000},"page":"72-77","source":"Crossref","is-referenced-by-count":37,"title":["Outcome of fractionated stereotactic radiotherapy in patients with pituitary adenomas resistant to conventional treatments: a 5\u00b725\u2010year follow\u2010up study"],"prefix":"10.1111","volume":"73","author":[{"given":"Camilla","family":"Schalin\u2010J\u00e4ntti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Valanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikko","family":"Tenhunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Set\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Paetau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Sane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauri","family":"Kouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,6,14]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"93","article-title":"Non\u2010functioning pituitary adenomas","volume":"28","author":"Chanson P.","year":"2005","journal-title":"Journal of Endocrinological Investigation"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb02913.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.8370847.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.11.3574"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-005-5087-0"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(96)90099-2"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1991.tb00312.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2004.02138.x"},{"key":"e_1_2_6_10_2","first-page":"502","article-title":"The long\u2010term side effects of radiation therapy for benign brain tumors in adults","volume":"74","author":"Al\u2010Mefty O.","year":"1991","journal-title":"Journal of Neurosurgery"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0936-6555(05)80885-4"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00335-0"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2005.07.004"},{"key":"e_1_2_6_14_2","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1210\/jc.2003-031584","article-title":"Growth hormone and pituitary radiotherapy, but not serum insulin\u2010like growth factor\u2010I concentrations, predict excess mortality in patients with acromegaly","volume":"84","author":"Ayuk J.","year":"2004","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1381"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.3171\/jns.2004.100.3.0438"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.09.058"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006123-199601000-00024"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021663"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.177.4.1770919"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2006.02506.x"},{"issue":"5","key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3171\/jns.2002.97.supplement_5.0408","article-title":"Radiosurgery for residual or recurrent nonfunctioning pituitary adenoma","volume":"97","author":"Sheehan J.P.","year":"2002","journal-title":"Journal of Neurosurgery"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009980404404"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00853.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1096-6374(00)80021-0"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.12.012"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0311"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2003.01770.x"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2005-9998"},{"key":"e_1_2_6_31_2","first-page":"129","article-title":"Treatment of extensively invasive (giant) prolactinomas with bromocriptine","volume":"105","author":"Grebe S.K.","year":"1992","journal-title":"New Zealand Medical Journal"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000223445.22938.BD"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.2009.03755.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.2009.03755.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T11:47:29Z","timestamp":1698752849000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.2009.03755.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,14]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1111\/j.1365-2265.2009.03755.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03755.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,14]]}}}